Koryx Copper Intersects 98.00 M @ 0.43% Cu Eq, Including 4 M @ 1.12% Cu Eq and 2 M @ 1.47% Cu Eq
Significant copper and molybdenum intersections include: HM17: 0.93% CuEq over 12 meters from near surface including 4 m @ 1.52% […]
Revival Gold Agrees to Acquire Ensign Minerals and Announces Concurrent C$7 Million Equity Financing
Creating One of the Largest Gold Development Companies in the United States with an Enhanced Platform for Heap Leach GoldProduction from […]
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
Vancouver, Canada, April 10, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “company”), a […]
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
LOS ALTOS, Calif., April 10, 2024 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for […]
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused […]
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
HOOKIPA announces alignment with FDA on pivotal trial design and protocol for HB-200 in combination with pembrolizumab HB-200 program receives […]
Colliers adds market leader in Philadelphia
TORONTO and PHILADELPHIA, April 10, 2024 (GLOBE NEWSWIRE) — Leading diversified professional services and investment management firm Colliers (NASDAQ and […]
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel […]
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Extended the Strategic Collaboration with Gilead Sciences Extended the Strategic Collaboration with Sanofi to Develop Novel Orally Available Targeted Protein […]
Nova Vision Acquisition Corp. Announces Additional Contribution to Trust Account to Extend Period to Consummate Business Combination to May 10, 2024
Singapore, April 10, 2024 (GLOBE NEWSWIRE) — Nova Vision Acquisition Corp. (NASDAQ: NOVV, the “Company”), a special purpose acquisition company, […]
